Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 17/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.48 |
| ▸ | MTOR | P42345 | 2/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.46 |
| ▸ | ATR | Q13535 | 1/20 | 0.45 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.45 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.45 |
| ▸ | PRKDC | P78527 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2397365 | 1.00 | PIK3CD (0.51) | PIK3CDCYP3A4PIK3CAMTORPIK3CB | |
| SCHEMBL2396961 | 0.93 | PIK3CA (0.51) | PIK3CDPIK3CAMTORPIK3CBPIK3CG | |
| SCHEMBL2395010 | 0.92 | PIK3CA (0.49) | PIK3CDPIK3CAMTORPIK3CBPIK3CG | |
| SCHEMBL2394451 | 0.90 | PIK3CA (0.54) | PIK3CDPIK3CAMTORPIK3CBPIK3CG | |
| SCHEMBL2394633 | 0.90 | PIK3CA (0.58) | PIK3CDPIK3CAMTORPIK3CBPIK3CG | |
| SCHEMBL2397198 | 0.88 | PIK3CD (0.67) | PIK3CDCYP3A4PIK3CAMTORPIK3CB | |
| SCHEMBL2397203 | 0.88 | PIK3CD (0.67) | PIK3CDCYP3A4PIK3CAMTORPIK3CB | |
| SCHEMBL13885983 | 0.87 | PIK3CD (0.49) | PIK3CDPIK3CAMTORPIK3CBPIK3CG | |
| SCHEMBL2394812 | 0.86 | PIK3CA (0.50) | PIK3CDPIK3CAMTORPIK3CBPIK3CG | |
| SCHEMBL12267760 | 0.86 | PIK3CD (0.57) | PIK3CDPIK3CAMTORPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | US | claimed |
| EP-2215090-B1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-03-04 | — | — | EP | disclosed |
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | PIK3CA, PIK3CD, PI4KA | PIK3CD 2/4885CYP3A4 1297/4885PIK3CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.